Antineoplastic Compounds Inhibiting CK2 Phosphorylation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current approaches to inhibit Casein Kinase 2 (CK2)-mediated phosphorylation, such as using peptides, face limitations including poor cell penetration, stability issues, and high costs, while small molecules like 4,5,6,7-tetrabromotriazole and other compounds show limited antitumoral activity in cancer models.
Innovation Solution
Development of chemical compounds with specific structural groups that directly or indirectly interact with the phosphoacceptor site on CK2 substrates, inhibiting CK2-mediated phosphorylation by binding to the phosphorylation domain or inducing conformational changes, thereby blocking enzyme-substrate interaction or phosphate transfer, which are synthesized and validated through molecular modeling and screening.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If cyclic peptides are used to block CK2 phosphorylation site, then CK2-mediated phosphorylation is inhibited, but cell penetration is poor and stability issues occur
Solution Approach 1:
The patent uses small molecule compounds as intermediaries that can penetrate cell membranes and deliver the inhibitory effect to CK2 substrates. These small molecules act as mediators between the external environment and the intracellular CK2 phosphorylation site, achieving inhibition without requiring the parent compound to enter the cell.
Solution Approach 2:
The patent replaces the mechanical/physical approach of using peptide structures that physically block the phosphorylation site with a chemical approach using small molecules that induce conformational changes or compete for binding, substituting the mechanical blocking mechanism with a chemical interaction mechanism.
2Reliability
If cyclic peptides are used to inhibit CK2, then phosphorylation is blocked, but costs are high and stability is poor
Solution Approach 1:
The patent employs small molecule compounds that are cheaper to synthesize and manufacture compared to cyclic peptides. These small molecules can be produced through established chemical synthesis routes, making them more cost-effective for pharmaceutical production while maintaining the desired biological activity.
Solution Approach 2:
The patent changes the chemical parameters of the inhibitory compound by transitioning from peptide-based structures to small molecule structures. This parameter change includes modifying molecular weight, chemical composition, and structural complexity, resulting in compounds that are more stable and easier to manufacture.
3Reliability
If small molecules like 4,5,6,7-tetrabromotriazole are used, then CK2 inhibition is achieved, but antitumoral activity is limited
Solution Approach 1:
The patent applies local quality by designing small molecules with specific structural features and functional groups that are localized to interact with particular regions of the CK2 substrate. This localized interaction enhances the biological effect and antitumoral activity while maintaining CK2 inhibition.
Solution Approach 2:
The patent creates composite molecular structures by combining different chemical moieties and functional groups within the small molecule framework. This composite approach allows the molecule to simultaneously achieve CK2 inhibition and enhanced antitumoral activity through multiple interaction mechanisms.
Data Source
Figure 1
AI summary
Chemical compounds identified by in silico molecular modelling, and having an structure that allows the blocking of the phosphorylation event, through the interaction of such compounds with the phosphorylation domain or its milieu in the substrates of the Casein Kinase 2 enzyme. This invention comprises also the pharmaceutical compositions containing such compounds, and their use in the preparation of medicines for the treatment of diseases related with neoplasic processes.